Byetta® (Exenatide) is a diabetic medication manufactured by Amylin Pharmaceuticals and Eli Lilly & Company. Byetta® is an injectable medication prescribed by physicians for the treatment of high insulin levels in patients with type-2 diabetes. If taken prior to the first and last meal of the day, Byetta® is claimed to help patients better control blood sugar levels. Byetta® is classified as an incretin mimetic drug and is believed to improve patients’ blood glucose levels by enhancing how the pancreas responds to the ingestion of food, suppressing the liver from producing unneeded sugars, and slowing down the emptying of the stomach.
Byetta® has been known to cause many serious side effects such as cancer. Patients have reported severe toxic allergic reactions, pancreatic cancer, acute pancreatitis, hyperglycemia, kidney damage, kidney failure which lead to dialysis and kidney transplants, dangerous high blood sugar levels, and hypoglycemia (low blood sugar). Ongoing side effects reported include: dizziness; fatigue; sweating; cold/hot sweats; vomiting; and consistent thirst.